Jonathan Sherlock

4.8k total citations · 3 hit papers
20 papers, 3.6k citations indexed

About

Jonathan Sherlock is a scholar working on Immunology, Rheumatology and Dermatology. According to data from OpenAlex, Jonathan Sherlock has authored 20 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 11 papers in Rheumatology and 7 papers in Dermatology. Recurrent topics in Jonathan Sherlock's work include Psoriasis: Treatment and Pathogenesis (13 papers), Spondyloarthritis Studies and Treatments (8 papers) and Dermatology and Skin Diseases (7 papers). Jonathan Sherlock is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (13 papers), Spondyloarthritis Studies and Treatments (8 papers) and Dermatology and Skin Diseases (7 papers). Jonathan Sherlock collaborates with scholars based in United Kingdom, United States and Canada. Jonathan Sherlock's co-authors include J. Daniel, Robert A. Kastelein, Daniel M. Gorman, Wayne To, Maria Wiekowski, Tatyana Churakova, Brian W. P. Seymour, Sérgio A. Lira, Sandra Zurawski and Jonathon D. Sedgwick and has published in prestigious journals such as Nature, The Lancet and Nature Medicine.

In The Last Decade

Jonathan Sherlock

16 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

2003 2.3k citations J. Daniel, Jonathan Sherlock et al. Nature profile →
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

2012 791 citations Jonathan Sherlock, Barbara Joyce-Shaikh et al. Nature Medicine profile →
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

2024 42 citations James G. Krueger, Kilian Eyerich et al. Frontiers in Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Sherlock United Kingdom	12	2.8k	1.1k	615	495	494	20	3.6k
Manjiri Sathe United States	13	2.1k 0.7×	683 0.6×	461 0.7×	522 1.1×	298 0.6×	19	3.0k
Martine Chabaud France	10	1.6k 0.6×	989 0.9×	413 0.7×	664 1.3×	214 0.4×	12	2.6k
Joël A. G. van Roon Netherlands	37	1.7k 0.6×	1.1k 1.0×	343 0.6×	548 1.1×	221 0.4×	83	3.5k
Stamatis‐Nick C. Liossis Greece	34	1.9k 0.7×	1.5k 1.3×	181 0.3×	416 0.8×	1.1k 2.3×	100	4.0k
Hiroaki Ida Japan	30	1.3k 0.5×	1.1k 0.9×	387 0.6×	353 0.7×	178 0.4×	165	3.3k
Rizgar A. Mageed United Kingdom	32	2.0k 0.7×	882 0.8×	333 0.5×	292 0.6×	312 0.6×	112	3.2k
Birgitte Oppers‐Walgreen Netherlands	15	1.5k 0.5×	910 0.8×	320 0.5×	647 1.3×	160 0.3×	17	2.5k
Jean‐Louis Pasquali France	25	1.3k 0.5×	750 0.7×	230 0.4×	240 0.5×	166 0.3×	58	2.3k
Yojiro Arinobu Japan	26	1.5k 0.5×	448 0.4×	516 0.8×	281 0.6×	169 0.3×	77	2.8k
Yohei Iwata Japan	23	1.5k 0.5×	372 0.3×	125 0.2×	295 0.6×	806 1.6×	85	2.9k

Countries citing papers authored by Jonathan Sherlock

Since Specialization

Citations

This map shows the geographic impact of Jonathan Sherlock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Sherlock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Sherlock more than expected).

Fields of papers citing papers by Jonathan Sherlock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Sherlock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Sherlock. The network helps show where Jonathan Sherlock may publish in the future.

Co-authorship network of co-authors of Jonathan Sherlock

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Sherlock. A scholar is included among the top collaborators of Jonathan Sherlock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Sherlock. Jonathan Sherlock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ward, Amy, Colin J. Chu, Sarah E. Coupland, et al.. (2025). IL-23 drives uveitis by acting on a population of tissue-resident entheseal T cells. JCI Insight. 10(19).

Rahman, Proton, Iain B. McInnes, Atul Deodhar, et al.. (2024). Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical Rheumatology. 43(5). 1591–1604.

Chang, Leon, Brian L. Knight, Jocelyn Sendecki, et al.. (2024). P626 JNJ-77242113, an oral peptide selectively targeting the IL-23 receptor, demonstrates pharmacodynamic activity in rat and human colon tissue explants following oral dosing. Journal of Crohn s and Colitis. 18(Supplement_1). i1193–i1193. 2 indexed citations

Chang, Leon, Jocelyn Sendecki, Jonathan Sherlock, et al.. (2024). Su1738 JNJ-77242113, AN ORAL PEPTIDE SELECTIVELY TARGETING THE IL-23 RECEPTOR, DEMONSTRATES PHARMACODYNAMIC ACTIVITY IN RAT AND HUMAN COLON TISSUE EXPLANTS FOLLOWING ORAL DOSING. Gastroenterology. 166(5). S–791. 1 indexed citations

Krueger, James G., Kilian Eyerich, Vijay K. Kuchroo, et al.. (2024). IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Frontiers in Immunology. 15. 1331217–1331217. 42 indexed citations breakdown →

Sharma, Srilakshmi M., Andrew D. Foers, Jonathan Sherlock, et al.. (2021). The Cellular Composition of the Uveal Immune Environment. Frontiers in Medicine. 8. 721953–721953. 14 indexed citations

Bridgewood, Charlie, et al.. (2020). Interleukin‐23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy. Immunological Reviews. 294(1). 27–47. 66 indexed citations

McGonagle, Dennis, Iain B. McInnes, Bruce Kirkham, Jonathan Sherlock, & Robert J. Moots. (2019). The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Annals of the Rheumatic Diseases. 78(9). 1167–1178. 160 indexed citations

Dakin, Stephanie G., Mark Coles, Jonathan Sherlock, et al.. (2018). Pathogenic stromal cells as therapeutic targets in joint inflammation. Nature Reviews Rheumatology. 14(12). 714–726. 79 indexed citations

10.

Sherlock, Jonathan, Peter C. Taylor, Christopher D. Buckley, & J. Daniel. (2015). Spondyloarthropathy: interleukin 23 and disease modification. The Lancet. 385(9982). 2017–2018. 12 indexed citations

11.

Sherlock, Jonathan, Peter C. Taylor, & Christopher D. Buckley. (2014). The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases. Current Opinion in Rheumatology. 27(1). 71–75. 24 indexed citations

12.

Sherlock, Jonathan & J. Daniel. (2013). Interleukin-23: a promising therapeutic target in seronegative spondyloarthropathy. Current Opinion in Pharmacology. 13(3). 445–448. 8 indexed citations

13.

Sherlock, Jonathan, Christopher D. Buckley, & J. Daniel. (2013). The critical role of interleukin-23 in spondyloarthropathy. Molecular Immunology. 57(1). 38–43. 41 indexed citations

14.

Sherlock, Jonathan, Barbara Joyce-Shaikh, Scott Turner, et al.. (2013). Interleukin 23 is critical in the pathogenesis of spondyloarthropathy and acts on a novel population of interleukin 23R+ entheseal resident cells. The Lancet. 381. S14–S14.

15.

Sherlock, Jonathan, Andrew Filer, John D. Isaacs, & Christopher D. Buckley. (2013). What can rheumatologists learn from translational cancer therapy?. Arthritis Research & Therapy. 15(3). 114–114. 5 indexed citations

16.

Sherlock, Jonathan, Barbara Joyce-Shaikh, Scott Turner, et al.. (2012). IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells. Nature Medicine. 18(7). 1069–1076. 791 indexed citations breakdown →

17.

Daniel, J. & Jonathan Sherlock. (2011). Autoimmunity's collateral damage: Gut microbiota strikes 'back'. Nature Medicine. 17(9). 1055–1056. 32 indexed citations

18.

Hou, Tie Zheng, Jonas Byström, Jonathan Sherlock, et al.. (2010). A distinct subset of podoplanin (gp38) expressing F4/80+ macrophages mediate phagocytosis and are induced following zymosan peritonitis. FEBS Letters. 584(18). 3955–3961. 35 indexed citations

19.

Carruthers, David & Jonathan Sherlock. (2009). Evidence-based management of ANCA vasculitis. Best Practice & Research Clinical Rheumatology. 23(3). 367–378. 11 indexed citations

20.

Daniel, J., Jonathan Sherlock, Yi Chen, et al.. (2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 421(6924). 744–748. 2297 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact